{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:31Z","timestamp":1791896491412,"version":"4.3.4"},"reference-count":53,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:p>OBJECTIVE. Neural tube defects (NTDs) are preventable through preconceptional and periconceptional folic acid intake. Although decreases in the prevalence of NTDs have been reported since folic acid fortification of United States grain products began, it is not known whether folic acid plays a role in reducing the severity of occurring NTDs. Our aim was to determine whether survival among infants born with spina bifida and encephalocele has improved since folic acid fortification and to measure the effects of selected maternal, pregnancy, and birth characteristics on first-year (infant) survival rates.<\/jats:p>\n               <jats:p>METHODS. A retrospective cohort study was conducted and included 2841 infants with spina bifida and 638 infants with encephalocele who were born between 1995 and 2001 and were registered in any of 16 participating birth defects monitoring programs in the United States. First-year survival rates for both spina bifida and encephalocele cohorts were measured with Kaplan-Meier estimation; factors associated with improved chances of first-year survival, including birth before or during folic acid fortification, were measured with Cox proportional-hazards regression analysis.<\/jats:p>\n               <jats:p>RESULTS. Infants with spina bifida experienced a significantly improved first-year survival rate of 92.1% (adjusted hazard ratio: 0.68; 95% confidence interval: 0.50\u20130.91) during the period of mandatory folic acid fortification, compared with a 90.3% survival rate for those born before fortification. Infants with encephalocele had a statistically nonsignificant increase in survival rates, ie, 79.1% (adjusted hazard ratio: 0.76; 95% confidence interval: 0.51\u20131.13) with folic acid fortification, compared with 75.7% for earlier births.<\/jats:p>\n               <jats:p>CONCLUSIONS. Folic acid may play a role in reducing the severity of NTDs in addition to preventing the occurrence of NTDs. This phenomenon contributes to our understanding of the efficacy of folic acid. Additionally, as survival of NTD-affected infants improves, health care, education, and family support must expand to meet their needs.<\/jats:p>","DOI":"10.1542\/peds.2005-1364","type":"journal-article","created":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T19:23:43Z","timestamp":1141241023000},"page":"803-813","source":"Crossref","is-referenced-by-count":88,"title":["Survival of Infants With Neural Tube Defects in the Presence of Folic Acid Fortification"],"prefix":"10.1542","volume":"117","author":[{"given":"Kirk A.","family":"Bol","sequence":"first","affiliation":[{"name":"Colorado Responds to Children With Special Needs, Colorado Department of Public Health and Environment, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne S.","family":"Collins","sequence":"additional","affiliation":[{"name":"JC Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell S.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Maternal and Child Health, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the National Birth Defects Prevention Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,3,1]]},"reference":[{"key":"2021120820134539500_R1","doi-asserted-by":"crossref","unstructured":"Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr.\u20082000;30:313\u2013332","DOI":"10.1067\/mpp.2000.112052"},{"key":"2021120820134539500_R2","doi-asserted-by":"crossref","unstructured":"Frey L, Hauser WA. Epidemiology of neural tube defects. Epilepsia.\u20082003;3:4\u201313","DOI":"10.1046\/j.1528-1157.44.s3.2.x"},{"key":"2021120820134539500_R3","unstructured":"Hall JG, Friedman JM, Kenna BA, Popkin J, Jawanda M, Arnold W. Clinical, genetic, and epidemiological factors in neural tube defects. Am J Hum Genet.\u20081988;43:827\u2013837"},{"key":"2021120820134539500_R4","doi-asserted-by":"crossref","unstructured":"Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med.\u20081992;327:1832\u20131835","DOI":"10.1056\/NEJM199212243272602"},{"key":"2021120820134539500_R5","doi-asserted-by":"crossref","unstructured":"Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet.\u20081991;338:131\u2013137","DOI":"10.1016\/0140-6736(91)90133-A"},{"key":"2021120820134539500_R6","doi-asserted-by":"crossref","unstructured":"Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA.\u20081993;269:1257\u20131261","DOI":"10.1001\/jama.269.10.1257"},{"key":"2021120820134539500_R7","doi-asserted-by":"crossref","unstructured":"Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA.\u20081988;260:3141\u20133145","DOI":"10.1001\/jama.260.21.3141"},{"key":"2021120820134539500_R8","doi-asserted-by":"crossref","unstructured":"Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. Teratology.\u20081996;53:345\u2013351","DOI":"10.1002\/(SICI)1096-9926(199606)53:6<345::AID-TERA5>3.0.CO;2-Z"},{"key":"2021120820134539500_R9","doi-asserted-by":"crossref","unstructured":"Smithells RW, Sheppard S, Schorah CJ, et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child.\u20081981;56:911\u2013918","DOI":"10.1136\/adc.56.12.911"},{"key":"2021120820134539500_R10","doi-asserted-by":"crossref","unstructured":"Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology.\u20081995;6:219\u2013226","DOI":"10.1097\/00001648-199505000-00005"},{"key":"2021120820134539500_R11","doi-asserted-by":"crossref","unstructured":"Sheppard S, Nevin NC, Seller MJ, et al. Neural tube defect recurrence after \u201cpartial\u201d vitamin supplementation. J Med Genet.\u20081989;26:326\u2013329","DOI":"10.1136\/jmg.26.5.326"},{"key":"2021120820134539500_R12","doi-asserted-by":"crossref","unstructured":"Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed).\u20081981;282:1509\u20131511","DOI":"10.1136\/bmj.282.6275.1509"},{"key":"2021120820134539500_R13","doi-asserted-by":"crossref","unstructured":"Holmes-Siedle M, Lindenbaum RH, Galliard A. Recurrence of neural tube defect in a group of at risk women: a 10 year study of Pregnavite Forte F. J Med Genet.\u20081992;29:134\u2013135","DOI":"10.1136\/jmg.29.2.134"},{"key":"2021120820134539500_R14","doi-asserted-by":"crossref","unstructured":"Stevenson RE, Allen WP, Pai GS, et al. Decline in prevalence of neural tube defects in a high-risk region of the United States. Pediatrics.\u20082000;106:677\u2013683","DOI":"10.1542\/peds.106.4.677"},{"key":"2021120820134539500_R15","doi-asserted-by":"crossref","unstructured":"Wild J, Read AP, Sheppard S, et al. Recurrent neural tube defects, risk factors and vitamins. Arch Dis Child.\u20081986;61:440\u2013444","DOI":"10.1136\/adc.61.5.440"},{"key":"2021120820134539500_R16","unstructured":"Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep.\u20081992;41(RR-14):1\u20137"},{"key":"2021120820134539500_R17","unstructured":"Institute of Medicine. Dietary Reference Intake: Folate, Other B Vitamins, and Choline Washington, DC: National Academy Press; 1998"},{"key":"2021120820134539500_R18","unstructured":"Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist.\u20081996;61:8781\u20138797"},{"key":"2021120820134539500_R19","doi-asserted-by":"crossref","unstructured":"Williams LJ, Mai CT, Edmonds LD, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology.\u20082002;66:33\u201339","DOI":"10.1002\/tera.10060"},{"key":"2021120820134539500_R20","doi-asserted-by":"crossref","unstructured":"Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA.\u20082001;285:2981\u20132986","DOI":"10.1001\/jama.285.23.2981"},{"key":"2021120820134539500_R21","doi-asserted-by":"crossref","unstructured":"Correa A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. The metropolitan Atlanta congenital defects program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res Part A Clin Mol Teratol.\u20082003;67:617\u2013624","DOI":"10.1002\/bdra.10111"},{"key":"2021120820134539500_R22","doi-asserted-by":"crossref","unstructured":"Feldkamp M, Friedrichs M, Carey JC. Decreasing prevalence of neural tube defects in Utah, 1985\u20132000. Teratology.\u20082002;66(suppl 1):S23\u2014S28.","DOI":"10.1002\/tera.90006"},{"key":"2021120820134539500_R23","doi-asserted-by":"crossref","unstructured":"Castilla EE, Orioli IM, Lopez-Camelo JS, Dutra Mda G, Nazer-Herrera J, Latin American Collaborative Study of Congenital Malformations. Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet A.\u20082003;123:123\u2013128","DOI":"10.1002\/ajmg.a.20230"},{"key":"2021120820134539500_R24","unstructured":"Petrini J, Damus K, Johnston R Jr. Trends in infant mortality attributable to birth defects: United States, 1980\u20131995. MMWR Morb Mortal Wkly Rep.\u20081998;47:773\u2013778"},{"key":"2021120820134539500_R25","doi-asserted-by":"crossref","unstructured":"Davidoff MJ, Petrini J, Damus K, Russell RB, Mattison D. Neural tube defect-specific infant mortality in the United States. Teratology.\u20082002;66(suppl 1):S17\u2013S22","DOI":"10.1002\/tera.90005"},{"key":"2021120820134539500_R26","doi-asserted-by":"crossref","unstructured":"Linhart Y, Bashiri A, Maymon E, et al. Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. Eur J Obstet Gynecol Reprod Biol.\u20082000;90:43\u201349","DOI":"10.1016\/S0301-2115(99)00196-7"},{"key":"2021120820134539500_R27","doi-asserted-by":"crossref","unstructured":"Siffel C, Wong LY, Olney RS, Correa A. Survival of infants diagnosed with encephalocele in Atlanta, 1979\u201398. Paediatr Perinat Epidemiol.\u20082003;17:40\u201348","DOI":"10.1046\/j.1365-3016.2003.00471.x"},{"key":"2021120820134539500_R28","doi-asserted-by":"crossref","unstructured":"Wong LY, Paulozzi LJ. Survival of infants with spina bifida: a population study, 1979\u201394. Paediatr Perinat Epidemiol.\u20082001;15:374\u2013378","DOI":"10.1046\/j.1365-3016.2001.00371.x"},{"key":"2021120820134539500_R29","doi-asserted-by":"crossref","unstructured":"Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2001 period: linked birth\/infant death data set. Natl Vital Stat Rep.\u20082003;52:1\u201328","DOI":"10.1037\/e558952006-001"},{"key":"2021120820134539500_R30","doi-asserted-by":"crossref","unstructured":"Forrester MB, Merz RD. First-year mortality rates for selected birth defects, Hawaii, 1986\u20131999. Am J Med Genet.\u20082003;119:311\u2013318","DOI":"10.1002\/ajmg.a.20151"},{"key":"2021120820134539500_R31","doi-asserted-by":"crossref","unstructured":"Nembhard WN, Waller DK, Sever LE, Canfield MA. Patterns of first-year survival among infants with selected congenital anomalies in Texas, 1995\u20131997. Teratology.\u20082001;64:267\u2013275","DOI":"10.1002\/tera.1073"},{"key":"2021120820134539500_R32","unstructured":"Hart AC, Scmidt K, eds. International Classification of Diseases, 9th Revision, Clinical Modification 6th ed. Salt Lake City, UT: Ingenix\/St Anthony Publishing; 2004"},{"key":"2021120820134539500_R33","unstructured":"Druschel C, Hughes JP, Olsen C. Mortality among infants with congenital malformations, New York State, 1983 to 1988. Public Health Rep.\u20081996;111:359\u2013365"},{"key":"2021120820134539500_R34","doi-asserted-by":"crossref","unstructured":"Kotelchuck M. The adequacy of prenatal care utilization index: its US distribution and association with low birthweight. Am J Public Health.\u20081994;84:1486\u20131489","DOI":"10.2105\/AJPH.84.9.1486"},{"key":"2021120820134539500_R35","doi-asserted-by":"crossref","unstructured":"Bol KA, Rickard RS, Kirby RS. Case fatality among infants with congenital malformations by lethality. Birth Defects Res Part A Clin Mol Teratol.\u20082004;70:580\u2013585","DOI":"10.1002\/bdra.20066"},{"key":"2021120820134539500_R36","unstructured":"Allison PD. Survival Analysis Using the SAS System: A Practical Guide Cary, NC: SAS Institute; 1995"},{"key":"2021120820134539500_R37","doi-asserted-by":"crossref","unstructured":"Collett D. Modeling Survival Data in Medical Research Boca Raton, FL: CRS Press; 1994","DOI":"10.1007\/978-1-4899-3115-3"},{"key":"2021120820134539500_R38","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables (with discussion). J R Stat Soc.\u20081972;74:187\u2013220","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2021120820134539500_R39","unstructured":"SAS Institute. SAS Version 9.1 Cary, NC: SAS Institute; 2004"},{"key":"2021120820134539500_R40","unstructured":"Centers for Disease Control and Prevention. Natality Public-Use Tapes and CD-ROM and Statistical Export and Tabulation System (SETS) Hyattsville, MD: National Center for Health Statistics; 2002"},{"key":"2021120820134539500_R41","doi-asserted-by":"crossref","unstructured":"Watkins ML, Edmonds L, McClearn A, Mullins L, Mulinare J, Khoury M. The surveillance of birth defects: the usefulness of the revised US standard birth certificate. Am J Public Health.\u20081996;86:731\u2013734","DOI":"10.2105\/AJPH.86.5.731"},{"key":"2021120820134539500_R42","unstructured":"March of Dimes Foundation. Folic Acid and the Prevention of Birth Defects: a National Survey of Pre-Pregnancy Awareness and Behavior Among Women of Childbearing Age, 1995\u20132003 White Plains, NY: March of Dimes Foundation; 2003"},{"key":"2021120820134539500_R43","doi-asserted-by":"crossref","unstructured":"Kirby RS. Trends in labor induction in the United States: is it true that what goes up must come down?Birth.\u20082004;31:148\u2013151","DOI":"10.1111\/j.0730-7659.2004.00294.x"},{"key":"2021120820134539500_R44","doi-asserted-by":"crossref","unstructured":"Su M, Hannah WJ, Willan A, Ross S, Hannah ME, Term Breech Trial Collaborative Group. Planned caesarean section decreases the risk of adverse perinatal outcome due to both labour and delivery complications in the Term Breech Trial. BJOG.\u20082004;111:1065\u20131074","DOI":"10.1111\/j.1471-0528.2004.00266.x"},{"key":"2021120820134539500_R45","doi-asserted-by":"crossref","unstructured":"Anteby EY, Yagel S. Route of delivery of fetuses with structural anomalies. Eur J Obstet Gynecol Reprod Biol.\u20082003;106:5\u20139","DOI":"10.1016\/S0301-2115(02)00033-7"},{"key":"2021120820134539500_R46","doi-asserted-by":"crossref","unstructured":"Adzick NS, Sutton LN, Crombleholme TM, Flake AW. Successful fetal surgery for spina bifida. Lancet.\u20081998;352:1675\u20131676","DOI":"10.1016\/S0140-6736(98)00070-1"},{"key":"2021120820134539500_R47","doi-asserted-by":"crossref","unstructured":"Tulipan N, Bruner JP. Myelomeningocele repair in utero: a report of three cases. Pediatr Neurosurg.\u20081998;28:177\u2013180","DOI":"10.1159\/000028645"},{"key":"2021120820134539500_R48","doi-asserted-by":"crossref","unstructured":"Tulipan N. Intrauterine closure of myelomeningocele: an update. Neurosurg Focus.\u20082004;16:e2","DOI":"10.3171\/foc.2004.16.2.3"},{"key":"2021120820134539500_R49","doi-asserted-by":"crossref","unstructured":"Feuchtbaum LB, Currier RJ, Riggle S, Roberson M, Lorey FW, Cunningham GC. Neural tube defect prevalence in California (1990\u20131994): eliciting patterns by type of defect and maternal race\/ethnicity. Genet Test.\u20081999;3:265\u2013272","DOI":"10.1089\/109065799316572"},{"key":"2021120820134539500_R50","doi-asserted-by":"crossref","unstructured":"Kirby R, Petrini J, Alter C. Collecting and interpreting birth defects surveillance data by Hispanic ethnicity: a comparative study: the Hispanic Ethnicity Birth Defects Workgroup. Teratology.\u20082000;61:21\u201327","DOI":"10.1002\/(SICI)1096-9926(200001\/02)61:1\/2<21::AID-TERA5>3.0.CO;2-X"},{"key":"2021120820134539500_R51","doi-asserted-by":"crossref","unstructured":"Canfield MA, Annegers JF, Brender JD, Cooper SP, Greenberg F. Hispanic origin and neural tube defects in Houston\/Harris County, Texas, II: risk factors. Am J Epidemiol.\u20081996;143:12\u201324","DOI":"10.1093\/oxfordjournals.aje.a008653"},{"key":"2021120820134539500_R52","doi-asserted-by":"crossref","unstructured":"Shaw GM, Velie EM, Wasserman CR. Risk for neural tube defect-affected pregnancies among women of Mexican descent and white women in California. Am J Public Health.\u20081997;87:1467\u20131471","DOI":"10.2105\/AJPH.87.9.1467"},{"key":"2021120820134539500_R53","doi-asserted-by":"crossref","unstructured":"Berger KH, Bao-Ping Z, Copeland G. Mortality throughout early childhood for Michigan children born with congenital anomalies, 1992\u20131998. Birth Defects Res Part A Clin Mol Teratol.\u20082003;67:656\u2013661","DOI":"10.1002\/bdra.10118"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/3\/803\/1070849\/zpe00306000803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/3\/803\/1070849\/zpe00306000803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T23:52:55Z","timestamp":1639007575000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/3\/803\/68633\/Survival-of-Infants-With-Neural-Tube-Defects-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,3,1]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1364","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]}}}